Biotech Startups

1 investor

Trillium Health Care Products is a contract manufacturer of prescription and over-the-counter pharmaceutical and consumer products for North American companies, based in Brockville, Ontario. With over 50 years of experience, it manufactures a range of medications and health products while maintaining FDA and Health Canada compliance.

1 investor

Trinity Biotech develops and manufactures diagnostic products for the medical diagnostics market, selling directly in the United States and through international distributors and strategic partners in over 100 countries. Its US and Irish facilities are FDA and ISO registered.

1 investor

TrioMed develops portable peritoneal dialysis systems for patients requiring renal replacement therapy at home or while traveling.

1 investor

TripleW converts food waste into high-value biomaterials for use in circular economy applications. The company produces lactic acid, ethyl lactate, and related lactate compounds in various grades.

1 investor

TriviumVet is an Irish veterinary pharmaceutical company that develops prescription drugs for serious conditions in cats and dogs, including feline hypertrophic cardiomyopathy and pain in dogs. It focuses on treatment gaps where no satisfactory therapy exists and runs clinical studies to support its products.

1 investor

1 investor

TruTags makes microscopic, edible barcodes that can be applied to pharmaceuticals, life-critical consumables, and other products for authentication, tracking, and tracing. The tags are decoded via consumer mobile apps to verify product authenticity and monitor patient compliance.

1 investor

A supplier of parasitic wasps for natural pest control, specifically targeting pantry moths and food storage insects in residential kitchens.

1 investor

TTP (formerly The Technology Partnership) is a technology and product development company that works on projects across deep tech, life sciences, and health tech for international clients and start-ups. Founded in 1987, it operates a campus-based team of over 550 people delivering product development and engineering work.

1 investor

TTP Group incubates and develops new technology products and businesses, working with clients across multiple market sectors and investing in early-stage technology companies. Based outside Cambridge, UK, it has created over 20 businesses spanning product development, life sciences automation, and defense R&D.

1 investor

Roche develops diagnostics and pharmaceutical medicines to address major healthcare challenges and improve patient outcomes across prevention, treatment, and cure.

1 investor

Twenty Two develops AI-powered biosecurity infrastructure for screening and monitoring biological threats across the emerging bioeconomy. The platform provides automated customer screening, functional sequence prediction, and model safeguards to help organizations comply with dual-use research regulations.

1 investor

Twinn Health provides preventive whole-body MRI infrastructure, offering AI-structured reporting and longitudinal health data for imaging providers and wellness clinics, plus expert MRI interpretation support for individuals. Originating from research at Imperial College London, it focuses on early disease detection in emerging longevity markets across the UK and the Middle East.

1 investor

TwinStrand develops Duplex Sequencing technology, a genomic platform for improving accuracy in clinical medicine and life sciences research applications. The company works with partners to translate genomic research into products for human health and scientific discovery.

1 investor

Twilight develops injectable precision immunotherapies to train the body's immune system to treat chronic diseases at scale. The company targets conditions that existing therapies inadequately address, with a focus on neurological and immunological diseases.

1 investor

1 investor

Typewriter Therapeutics develops mRNA-based gene therapies using a platform for targeted insertion of therapeutic genes, building on transposon research from the University of Tokyo. It aims to treat patients with severe genetic disorders, with research facilities in Tokyo and Cambridge, USA.

1 investor

Tyris Therapeutics develops non-viral gene therapies using a proprietary DNA format (oDNA™) to treat rare and prevalent genetic diseases. The company aims to provide safer, controllable treatments that can accommodate genes of any size, with the ability to adjust dosing and allow for retreatment.

1 investor

1 investor

Ubique Biotech develops AI-designed synthetic reagents (antigen and antibody based) for precision diagnostics used in formats such as ELISA and rapid point-of-care tests. Founded in 2022, it focuses on affordable, scalable disease detection and screening without extensive laboratory infrastructure.

1 investor

UbiquiTx develops an AI-native platform for programmable modulation of the proteome, using modular constructs that pair AI-designed guide peptides with swappable effector enzymes to degrade, stabilize, or relocalize target proteins. The company runs a validation business and a therapeutic pipeline in oncology and regenerative disease.

1 investor

UCAN produces sports nutrition products powered by LIVSTEADY, a proprietary low-glycemic carbohydrate formulation designed to deliver sustained energy without rapid blood sugar spikes. The company offers energy gels, bars, drink mixes, and hydration products marketed to athletes and active consumers.

1 investor

UCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.

1 investor